Impact of taxanes on androgen receptor signaling  

作　　者：Shanshan Bai Bryan Y Zhang Yan Dong 

机构地区：[1]College of Life Sciences, Jilin University, Changchun 130012, China [2]Department of Structural and Cellular Biology, Tulane University School of Medicine, Tulane Cancer Center, New Orleans, LA 70112, USA [3]Lusher Charter School, New Orleans, LA 70115, USA

出　　处：《Asian Journal of Andrology》2019年第3期249-252,共4页亚洲男性学杂志（英文版）

基　　金：the following grants: National Institutes ofHealth/National Cancer Institute (NIH/NCI) RO1 CAI88609, Department of Defense W81XWH-15-1-0439, W81XWH-16-1-0317, and W81XWH-14-1-0485;National Natural Science Foundation of China Project 81430087.

摘　　要：The development and progression of metastatic castration-resistant prostate cancer is the major challenge in the treatment of advanced prostate cancer. The androgen receptor signaling pathway remains active in metastatic castration-resistant prostate cancer. Docetaxel and cabazitaxel are the first- and second-line chemotherapy, respectively, for patients with metastatic castration-resistant prostate cancer. These two taxanes, in general, function by (i) inhibiting mitosis and inducing apoptosis and (ii) preventing microtubule-dependent cargo trafficking. In prostate cancer, taxanes have been reported to inhibit the nuclear translocation and activity of the androgen receptor. However, whether this is attainable or not clinically remains controversial. In this review, we will provide a comprehensive view of the effects of taxanes on androgen receptor signaling in prostate cancer.

关 键 词：ANDROGEN RECEPTOR ANDROGEN RECEPTOR splice variant CABAZITAXEL DOCETAXEL prostate cancer TAXANE 

分 类 号：R[医药卫生]